NCT00387985已完成1 期
An Open-label, Single-dose, Randomized, 2-period Crossover, Bioequivalence Study Between the Current Formulation and the New Formulation of MOA-728 Administered Subcutaneously in Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- bioequivalence
研究概览
简要总结
Primary: To determine the bioequivalence between the new formulation and the current formulation of the investigational drug, MOA-728.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).
排除标准
- 未提供
结局指标
主要结局
bioequivalence
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Bioequivalence Study of CJ-30059Healthy VolunteersNCT02173912HK inno.N Corporation32
已完成
1 期
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed ConditionsHealthyNCT01634399Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fasting ConditionsHealthyNCT01634386Torrent Pharmaceuticals Limited
已完成
1 期
PK Comparison of GL2701 With Finasteride and Tamsulosin in CombinationBenign Prostatic Hyperplasia (BPH)NCT01829893Korea University Anam Hospital26
已完成
1 期
To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy SubjectsHealthyNCT02823171CTI BioPharma28